TY - JOUR
T1 - Predicted 3D structure for the human β2 adrenergic receptor and its binding site for agonists and antagonists
AU - Freddolino, Peter L.
AU - Kalani, M. Yashar S.
AU - Vaidehi, Nagarajan
AU - Floriano, Wely B.
AU - Hall, Spencer E.
AU - Trabanino, Rene J.
AU - Kam, Victor Wai Tak
AU - Goddard, William A.
PY - 2004/3/2
Y1 - 2004/3/2
N2 - We report the 3D structure of human β2 adrenergic receptor (AR) predicted by using the MembStruk first principles method. To validate this structure, we use the HierDock first principles method to predict the ligand-binding sites for epinephrine and norepinephrine and for eight other ligands, including agonists and antagonists to β2 AR and ligands not observed to bind β2 AR. The binding sites agree well with available mutagenesis data, and the calculated relative binding energies correlate reasonably with measured binding affinities. In addition, we find characteristic differences in the predicted binding sites of known agonists and antagonists that allow us to infer the likely activity of other ligands. The predicted ligand-binding properties validate the methods used to predict the 3D structure and function. This validation is a successful step toward applying these procedures to predict the 3D structures and function of the other eight subtypes of ARs, which should enable the development of subtype-specific antagonists and agonists with reduced side effects.
AB - We report the 3D structure of human β2 adrenergic receptor (AR) predicted by using the MembStruk first principles method. To validate this structure, we use the HierDock first principles method to predict the ligand-binding sites for epinephrine and norepinephrine and for eight other ligands, including agonists and antagonists to β2 AR and ligands not observed to bind β2 AR. The binding sites agree well with available mutagenesis data, and the calculated relative binding energies correlate reasonably with measured binding affinities. In addition, we find characteristic differences in the predicted binding sites of known agonists and antagonists that allow us to infer the likely activity of other ligands. The predicted ligand-binding properties validate the methods used to predict the 3D structure and function. This validation is a successful step toward applying these procedures to predict the 3D structures and function of the other eight subtypes of ARs, which should enable the development of subtype-specific antagonists and agonists with reduced side effects.
U2 - 10.1073/pnas.0308751101
DO - 10.1073/pnas.0308751101
M3 - Article
C2 - 14981238
AN - SCOPUS:1542267836
SN - 0027-8424
VL - 101
SP - 2736
EP - 2741
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 9
ER -